您的当前位置:首页 > 行业数据 > 与可比公司相比,公司估值较高,系公司作为全球多肽合成试剂领域龙头企业,具有一定的稀缺性
图片属性
图片格式:PNG 图片大小:148KB 图片尺寸:2327*594
同报告图片
 / 4
与可比公司相比,公司估值较高,系公司作为全球多肽合成试剂领域龙头企业,具有一定的稀缺性_第1页
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
与可比公司相比,公司估值较高,系公司作为全球多肽合成试剂领域龙头企业,具有一定的稀缺性_第2页
与可比公司相比,公司估值较高,系公司作为全球多肽合成试剂领域龙头企业,具有一定的稀缺性_第3页
与可比公司相比,公司估值较高,系公司作为全球多肽合成试剂领域龙头企业,具有一定的稀缺性_第4页
与可比公司相比,公司估值较高,系公司作为全球多肽合成试剂领域龙头企业,具有一定的稀缺性_第5页
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
所属报告: 昊帆生物-公司首次覆盖报告:多肽合成试剂行业龙头自有产能落地赋能长期发展-230720(33页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠